Carla Colombo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6690535/publications.pdf

Version: 2024-02-01

130	6,991	76294 40	62565 80
papers	citations	h-index	g-index

133	133	133	5967
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	13.9	1,308
2	ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clinical Nutrition, 2016, 35, 557-577.	2.3	367
3	Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis, 2011, 10, S29-S36.	0.3	332
4	Genetic Modifiers of Liver Disease in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2009, 302, 1076.	3.8	256
5	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology, 2002, 36, 1374-1382.	3.6	207
6	Analysis of risk factors for the development of liver disease associated with cystic fibrosis. Journal of Pediatrics, 1994, 124, 393-399.	0.9	177
7	Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology, 2002, 36, 1374-1382.	3.6	173
8	Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. Journal of Cystic Fibrosis, 2011, 10, S24-S28.	0.3	151
9	Liver disease in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2007, 13, 529-536.	1.2	150
10	Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. Journal of Pediatrics, 1990, 117, 482-489.	0.9	143
11	Defining DIOS and Constipation in Cystic Fibrosis With a Multicentre Study on the Incidence, Characteristics, and Treatment of DIOS. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 38-42.	0.9	143
12	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	13.9	140
13	Ursodeoxycholic acid therapy in cystic fibrosisâ€”associated liver disease: A dose-response study. Hepatology, 1992, 16, 924-930.	3.6	127
14	Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology, 1992, 15, 677-684.	3.6	123
15	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	5.2	114
16	Liver and Biliary Problems in Cystic Fibrosis. Seminars in Liver Disease, 1998, 18, 227-235.	1.8	111
17	BMD and Body Composition in Children and Young Patients Affected by Cystic Fibrosis. Journal of Bone and Mineral Research, 2006, 21, 388-396.	3.1	98
18	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 905-913.	1.8	95

#	Article	IF	Citations
19	Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatric Pulmonology, 2005, 40, 15-21.	1.0	88
20	Liver Disease in Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S49-S55.	0.9	87
21	Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). European Journal of Human Genetics, 2007, 15, 1230-1238.	1.4	85
22	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
23	Cystic Fibrosisâ€"related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 443-448.	0.9	80
24	Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology, 1990, 12, 322-334.	3.6	78
25	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.3	74
26	Congenital Cytomegalovirus Infection: Update on Diagnosis and Treatment. Microorganisms, 2020, 8, 1516.	1.6	70
27	Clinical Features and Genotypeâ€Phenotype Correlations in Children With Progressive Familial Intrahepatic Cholestasis Type 3 Related to ABCB4 Mutations. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 73-83.	0.9	64
28	Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transplant International, 2006, 19, 726-731.	0.8	62
29	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30.	0.3	62
30	Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. European Journal of Endocrinology, 2015, 173, 29-36.	1.9	60
31	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
32	BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
33	Genotypeâ€"phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. Journal of Medical Genetics, 2017, 54, 224-235.	1.5	52
34	Liver involvement in cystic fibrosis. Journal of Hepatology, 1999, 31, 946-954.	1.8	51
35	Effects of liver transplantation on the nutritional status of patients with cystic fibrosis*. Transplant International, 2005, 18, 246-255.	0.8	51
36	International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. Journal of Cystic Fibrosis, 2016, 15, 531-539.	0.3	51

#	Article	IF	Citations
37	Hepatobiliary Disease in Cystic Fibrosis. Seminars in Liver Disease, 1994, 14, 259-269.	1.8	50
38	ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. Journal of Gastroenterology, 2016, 51, 271-280.	2.3	45
39	Benefits of breastfeeding in cystic fibrosis: A singleâ€centre followâ€up survey. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1228-1232.	0.7	43
40	Clinical expression of patients with the D1152H CFTR mutation. Journal of Cystic Fibrosis, 2015, 14, 447-452.	0.3	43
41	Amniotic Mesenchymal Stem Cells: A New Source for Hepatocyte-Like Cells and Induction of CFTR Expression by Coculture with Cystic Fibrosis Airway Epithelial Cells. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-15.	3.0	42
42	The implementation of standards of care in Europe: State of the art. Journal of Cystic Fibrosis, 2011, 10, S7-S15.	0.3	41
43	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
44	Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines. Journal of Cystic Fibrosis, 2017, 16, 510-518.	0.3	38
45	Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 328-334.	0.3	37
46	BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
47	Liver involvement in cystic fibrosis: primary organ damage or innocent bystander?. Journal of Hepatology, 2004, 41, 1041-1044.	1.8	35
48	Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respiratory Medicine,the, 2013, 1, 377-385.	5.2	34
49	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577.	0.3	34
50	A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. Journal of Cystic Fibrosis, 2021, 20, 828-834.	0.3	32
51	Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax, 2011, 66, 260-261.	2.7	31
52	Validation of a predictive survival model in Italian patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 24-29.	0.3	30
53	Caregiver burden and vocational participation among parents of adolescents with CF. Pediatric Pulmonology, 2016, 51, 243-252.	1.0	29
54	Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulmonary Medicine, 2018, 18, 196.	0.8	29

#	Article	IF	Citations
55	Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP). BMJ Open, 2017, 7, e014931.	0.8	28
56	Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis, 2018, 17, 375-382.	0.3	28
57	The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 245.	3.5	27
58	Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis. Journal of Cystic Fibrosis, 2014, 13, 455-460.	0.3	26
59	Cystic fibrosis mortality trend in Italy from 1970 to 2011. Journal of Cystic Fibrosis, 2015, 14, 267-274.	0.3	26
60	The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 1305-1319.	0.4	26
61	Growth Assessment of Paediatric Patients With CF Comparing Different Auxologic Indicators: A Multicentre Italian Study. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 335-342.	0.9	25
62	Efficacy and Tolerability of Creon for Children in Infants and Toddlers With Pancreatic Exocrine Insufficiency Caused by Cystic Fibrosis. Pancreas, 2009, 38, 693-699.	0.5	24
63	Insulin secretion, nutritional status and respiratory function in cystic fibrosis patients with normal glucose tolerance. Clinical Nutrition, 2012, 31, 118-123.	2.3	24
64	Dietary and Circulating Polyunsaturated Fatty Acids in Cystic Fibrosis: Are They Related to Clinical Outcomes?. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 660-665.	0.9	23
65	Estimating body composition from skinfold thicknesses and bioelectrical impedance analysis in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 784-791.	0.3	23
66	Tumor and normal thyroid spheroids: from tissues to zebrafish. Minerva Endocrinology, 2018, 43, 1-10.	0.6	23
67	Bile Acid Malabsorption in Cystic Fibrosis With and Without Pancreatic Insufficiency. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 556-562.	0.9	22
68	Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction. European Journal of Human Genetics, 2014, 22, 633-639.	1.4	20
69	Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease. Journal of Pediatrics, 2016, 177, 59-65.e1.	0.9	20
70	Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS ONE, 2019, 14, e0225004.	1.1	20
71	Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. Journal of Cystic Fibrosis, 2022, 21, 220-226.	0.3	20
72	Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. Infection, 2022, 50, 671-679.	2.3	20

#	Article	IF	Citations
73	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis. Italian Journal of Pediatrics, 2018, 44, 93.	1.0	19
74	Successful ceftazidimeâ€avibactam treatment of postâ€surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis. Transplant Infectious Disease, 2019, 21, e13082.	0.7	19
75	Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Research, 2021, 7, 00411-2021.	1.1	19
76	Evaluation of an oral ursodeoxycholic acid load in the assessment of bile acid malabsorption in cystic fibrosis. Digestive Diseases and Sciences, 1983, 28, 306-311.	1.1	18
77	Changes in Cesarean Delivery in an Italian University Hospital, 1982-1996: A Comparison with the National Trend. Birth, 1999, 26, 144-148.	1.1	18
78	SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020. PLoS ONE, 2021, 16, e0251527.	1.1	18
79	CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?. Diagnostics, 2020, 10, 1080.	1.3	17
80	Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation. ERJ Open Research, 2021, 7, 00614-2020.	1.1	17
81	Fetal cell microchimerism: a protective role in autoimmune thyroid diseases. European Journal of Endocrinology, 2015, 173, 111-118.	1.9	16
82	The long and winding road: stem cells for cystic fibrosis. Expert Opinion on Biological Therapy, 2018, 18, 281-292.	1.4	16
83	Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2963-2971.	1.8	15
84	Gap Junctions Are Involved in the Rescue of CFTR-Dependent Chloride Efflux by Amniotic Mesenchymal Stem Cells in Coculture with Cystic Fibrosis CFBE41o- Cells. Stem Cells International, 2018, 2018, 1-14.	1.2	15
85	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.3	15
86	Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 366-371.	0.3	14
87	Growth failure in cystic fibrosis: A true need for anabolic agents?. Journal of Pediatrics, 2005, 146, 303-305.	0.9	13
88	MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. Endocrine, 2018, 61, 36-41.	1.1	13
89	Human Rhinovirus Infection in Children with Cystic Fibrosis. Japanese Journal of Infectious Diseases, 2014, 67, 399-401.	0.5	13
90	Bowel ultrasound imaging in patients with cystic fibrosis: Relationship with clinical symptoms and CFTR genotype. Digestive and Liver Disease, 2016, 48, 271-276.	0.4	12

#	Article	IF	Citations
91	Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. Journal of Cystic Fibrosis, 2022, 21, 850-855.	0.3	12
92	Liver Disease in Cystic Fibrosis: Illuminating the Black Box. Hepatology, 2019, 69, 1379-1381.	3.6	11
93	Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, e33-e39.	0.3	11
94	Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulatorâ€related metabolic syndrome/CF screenâ€positive, inconclusive diagnosis. Pediatric Pulmonology, 2021, 56, 3785-3791.	1.0	11
95	Highlights of the ESPENâ€ESPGHANâ€ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 671-675.	0.9	9
96	Diet as a possible influencing factor in thyroid cancer incidence: the point of view of the nutritionist. Panminerva Medica, 2021, 63, 349-360.	0.2	9
97	Ventilation inhomogeneity is associated with OGTTâ€derived insulin secretory defects in cystic fibrosis. Pediatric Pulmonology, 2019, 54, 141-149.	1.0	8
98	Interaction between Streptococcus pneumoniae and Staphylococcus aureus in paediatric patients suffering from an underlying chronic disease. International Journal of Immunopathology and Pharmacology, 2015, 28, 497-507.	1.0	7
99	Letter regarding the article: â€œMultiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of â€œthyroid-checkedâ€•controlsâ€•by Kern etÂal.. European Journal of Medical Genetics, 2018, 61, 104-105.	0.7	7
100	Expiratory muscle strength and functional exercise tolerance in adults with cystic fibrosis: a crossâ€sectional study. Physiotherapy Research International, 2018, 23, e1720.	0.7	7
101	Challenges with optimizing nutrition in cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 533-544.	1.0	7
102	Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis. PLoS ONE, 2019, 14, e0213216.	1.1	7
103	Exercise capacity and ventilation inhomogeneity in cystic fibrosis: A crossâ€sectional study. Pediatric Pulmonology, 2020, 55, 394-400.	1.0	7
104	Change in Nutrient and Dietary Intake in European Children with Cystic Fibrosis after a 6-Month Intervention with a Self-Management mHealth Tool. Nutrients, 2021, 13, 1801.	1.7	7
105	Mutation-targeted personalised medicine for cystic fibrosis. Lancet Respiratory Medicine,the, 2014, 2, 863-865.	5.2	6
106	Remote support by multidisciplinary teams: A crucial means to cope with the psychological impact of the SARSâ€COVâ€2 pandemic on patients with cystic fibrosis and inflammatory bowel disease in Lombardia. International Journal of Clinical Practice, 2021, 75, e14220.	0.8	6
107	Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose. Pediatric Research, 2021, 89, 205-210.	1.1	5
108	Three months of COVID-19 in a pediatric setting in the center of Milan. Pediatric Research, 2021, 89, 1572-1577.	1.1	4

#	Article	IF	Citations
109	Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines, 2021, 9, 487.	2.1	4
110	SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. Journal of Cystic Fibrosis, 2022, 21, e113-e116.	0.3	4
111	Carbohydrate 19-9 Antigen Is Not a Marker of Liver Disease in Patients with Cystic Fibrosis. Clinical Chemistry and Laboratory Medicine, 2003, 41, 311-6.	1.4	3
112	Pancreatic Development in Newborn Guinea Pigs Fed Intact or Low-Hydrolyzed Protein Formulas. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 644-649.	0.9	3
113	Influence of Breast Feeding, and Adapted and Hydrolyzed Formulas on Biliary Bile Acids in Newborn Guinea Pigs. Neonatology, 2003, 83, 36-41.	0.9	2
114	No gender differences in growth patterns in a cohort of children with cystic fibrosis born between 1986 and 1995. Clinical Nutrition, 2019, 38, 1782-1787.	2.3	2
115	Cytokine storm syndrome in a young patient with cystic fibrosis. Pediatric Pulmonology, 2021, 56, 3435-3437.	1.0	2
116	Breastfeeding in Cystic Fibrosis: A Systematic Review on Prevalence and Potential Benefits. Nutrients, 2021, 13, 3263.	1.7	2
117	Prevalence and factors associated with urinary incontinence in females with cystic fibrosis: An Italian singleâ€center crossâ€sectional analysis. Pediatric Pulmonology, 2022, 57, 132-141.	1.0	2
118	The role of stem cells in cystic fibrosis disease modeling and drug discovery. Expert Opinion on Orphan Drugs, 2018, 6, 707-717.	0.5	1
119	Delphi poll to assess consensus on issues influencing long-term adherence to treatments in cystic fibrosis among Italian health care professionals. Patient Preference and Adherence, 2018, Volume 12, 2233-2241.	0.8	1
120	Cystic Fibrosis, New Frontier: Exploring the Functional Connectivity of the Brain Default Mode Network. Comment on Elce et al. Impact of Physical Activity on Cognitive Functions: A New Field for Research and Management of Cystic Fibrosis. Diagnostics 2020, 10, 489. Diagnostics, 2021, 11, 1001.	1.3	1
121	Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over. Journal of Cystic Fibrosis, 2022, , .	0.3	1
122	Improve knowledge and management of thyroid cancer: the role of the endocrinologist in a multidisciplinary team. Minerva Medica, 2022, 112, 689-691.	0.3	1
123	Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists. Health Science Reports, 2022, 5, .	0.6	1
124	Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV1, Lung Clearance Index and Peak Work Rate. Frontiers in Pediatrics, 0, 10, .	0.9	1
125	Limitations of the dichotomized 6-minute walk distance when computing lung allocation score for cystic fibrosis: a 16-year retrospective cohort study. Disability and Rehabilitation, 2023, 45, 2578-2584.	0.9	1
126	Cystic fibrosis transmembrane conductance-regulator modulators for children. Lancet Respiratory Medicine,the, 2017, 5, 536-537.	5.2	0

#	Article	IF	Citations
127	Liver Disease in Cystic Fibrosis. , 2021, , 93-113.		0
128	A case of testicular atrophy associated with cystic fibrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0
129	A case of testicular atrophy associated with cystic fibrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0
130	FAM83B is involved in thyroid cancer cell differentiation and migration. Scientific Reports, 2022, 12, .	1.6	0